LBLTF (Lattice Biologics) ROCE %: 0.00% (As of Jun. 2021)


What is Lattice Biologics ROCE %?

Lattice Biologics LBLTF -99.00% ROCE % is 0.00% as of Jun. 2021.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lattice Biologics's annualized ROCE % for the quarter that ended in Jun. 2021 was 0.00%.

Lattice Biologics  (OTCPK:LBLTF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lattice Biologics ROCE % Related Terms

Lattice Biologics ROCE % Historical Data

* Premium members only.

The historical data trend for Lattice Biologics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lattice Biologics ROCE % Chart

Lattice Biologics Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Sep16 Sep17 Sep18 Sep19 Sep20
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Lattice Biologics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Lattice Biologics ROCE % Calculation

Lattice Biologics's annualized ROCE % for the fiscal year that ended in Sep. 2020 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Sep. 2020 )  (A: Sep. 2019 )(A: Sep. 2020 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Sep. 2020 )  (A: Sep. 2019 )(A: Sep. 2020 )
=-0.442/( ( (2.275 - 7.685) + (3.018 - 7.832) )/ 2 )
=-0.442/( (-5.41+-4.814)/ 2 )
=-0.442/-5.112
=8.65 %

Lattice Biologics's ROCE % of for the quarter that ended in Jun. 2021 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2021 )  (Q: Mar. 2021 )(Q: Jun. 2021 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2021 )  (Q: Mar. 2021 )(Q: Jun. 2021 )
=-0.104/( ( (0.632 - 1.526) + (0.606 - 0.506) )/ 2 )
=-0.104/( ( -0.894 + 0.1 )/ 2 )
=-0.104/-0.397
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2021) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Lattice Biologics (LBLTF) has a ROCE % of 0.00% as of Jun. 2021.
Is Lattice Biologics' ROCE % too high?
Lattice Biologics' current ROCE % is 0.00%.
How does Lattice Biologics' ROCE % compare to ABT and MDT?
Lattice Biologics' ROCE % of 0.00% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lattice Biologics's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lattice Biologics stock overvalued right now?
Lattice Biologics (LBLTF) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Lattice Biologics (LBLTF), the current ROCE % is 0.00% as of Jun. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lattice Biologics Business Description

Address 512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714
Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The company's products include ADM dermis, DBM Putty, Bone scaffold, and others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.